3509 related articles for article (PubMed ID: 19167589)
1. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
2. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
3. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.
Olsson AG; Eriksson M; Johnson O; Kjellström T; Lanke J; Larsen ML; Pedersen T; Tikkanen MJ; Wiklund O;
Clin Ther; 2003 Jan; 25(1):119-38. PubMed ID: 12637115
[TBL] [Abstract][Full Text] [Related]
4. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
5. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
8. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
9. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
Ballantyne CM; Houri J; Notarbartolo A; Melani L; Lipka LJ; Suresh R; Sun S; LeBeaut AP; Sager PT; Veltri EP;
Circulation; 2003 May; 107(19):2409-15. PubMed ID: 12719279
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
[TBL] [Abstract][Full Text] [Related]
11. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
12. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention.
Ishii H; Nishio M; Takahashi H; Aoyama T; Tanaka M; Toriyama T; Tamaki T; Yoshikawa D; Hayashi M; Amano T; Matsubara T; Murohara T
Clin Ther; 2010 Dec; 32(14):2337-47. PubMed ID: 21353104
[TBL] [Abstract][Full Text] [Related]
13. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
Navarro JF; Mora C; Muros M; García-Idoate G
Nephron Clin Pract; 2003; 95(4):c128-35. PubMed ID: 14694274
[TBL] [Abstract][Full Text] [Related]
14. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
[TBL] [Abstract][Full Text] [Related]
15. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
Davidson M; Ma P; Stein EA; Gotto AM; Raza A; Chitra R; Hutchinson H
Am J Cardiol; 2002 Feb; 89(3):268-75. PubMed ID: 11809427
[TBL] [Abstract][Full Text] [Related]
16. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
Hunninghake DB; Ballantyne CM; Maccubbin DL; Shah AK; Gumbiner B; Mitchel YB
Clin Ther; 2003 Jun; 25(6):1670-86. PubMed ID: 12860491
[TBL] [Abstract][Full Text] [Related]
18. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
[TBL] [Abstract][Full Text] [Related]
20. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
